Date: 2013-03-22
Type of information: Development agreement
Compound: fully-human antibody-drug-conjugates
Company: APO-T (The Netherlands) LinXis (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease:
Details: LinXis, a Dutch oncology company developing linker technology for the conjugation of cytotoxic drugs to antibodies, has granted APO-T an exclusive worldwide license for the development and commercialization of fully human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ LX linker technology. In exchange, LinXis will receive milestone payments and royalties.
APO-T is focused on the development and commercialization of proprietary biotherapeutics for oncology. The company has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1.
Financial terms:
Latest news:
